Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Gene therapy is a new tool used in combating different diseases. The majority of gene therapy clinical trials are focused on cancer and so it was no coincidence that the first commercial treatment in 2003 was for neoplasia. Currently there are a wide variety of gene therapy proposals involving a large number of anti tumour molecular mechanisms that will conceivably pave the way for highly effective a treatment options. Despite the significant advances that how been made in gene therapy in the fight against cancer, its efficacy,safety and commercial availability are still limited. Ms. Chetana D. Patil | Ms. Siddhi Chavan | Mr. Ritesh Kadam "Gene Therapy for Cancer Treatment" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5 , August 2019, URL: https://www.ijtsrd.com/papers/ijtsrd26537.pdfPaper URL: https://www.ijtsrd.com/pharmacy/biotechnology-/26537/gene-therapy-for-cancer-treatment/ms-chetana-d-patil
Chimeric Antigen Receptors (paper with corresponding power point)Kevin B Hugins
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
This presentation summarizes data related to the CAR-T cell technology and its potential application for cancer therapy. This oral presentation was presented at the 39th PAMM winter meeting in Roma the 8th f February 2018 by Eric Raymond
It is early days, but the engineered expression of chimeric antigen receptors (CARs) on the surface of T cells the redirection of T‑cell specificitymay lead to improvements in clinical outcomes for patients with solid tumors.
This presentation focuses on the science of Gene Therapy, the techniques of germ-line and somatic gene therapy and the mechanism of curing diseases and disorders using gene therapy. The presentation starts by discussing some common basic terms from genetics and moves on to the historical development of gene therapy techniques in chronological order. The different types of gene therapy techniques and their mechanisms have been discussed in detail subsequently. In concluding slides, some commercially available gene therapy products are mentioned and challenges of gene-therapy techniques have been highlighted.
Final presentation for BIOL405, NSC, Spring 2014. Presented by Kevin Hugins and Duy-Khiem Chanh Pham. This presentation addressed the use of Chimeric Antigen Receptors for gene therapy for cancer. Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Gene therapy is a new tool used in combating different diseases. The majority of gene therapy clinical trials are focused on cancer and so it was no coincidence that the first commercial treatment in 2003 was for neoplasia. Currently there are a wide variety of gene therapy proposals involving a large number of anti tumour molecular mechanisms that will conceivably pave the way for highly effective a treatment options. Despite the significant advances that how been made in gene therapy in the fight against cancer, its efficacy,safety and commercial availability are still limited. Ms. Chetana D. Patil | Ms. Siddhi Chavan | Mr. Ritesh Kadam "Gene Therapy for Cancer Treatment" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5 , August 2019, URL: https://www.ijtsrd.com/papers/ijtsrd26537.pdfPaper URL: https://www.ijtsrd.com/pharmacy/biotechnology-/26537/gene-therapy-for-cancer-treatment/ms-chetana-d-patil
Chimeric Antigen Receptors (paper with corresponding power point)Kevin B Hugins
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
This presentation summarizes data related to the CAR-T cell technology and its potential application for cancer therapy. This oral presentation was presented at the 39th PAMM winter meeting in Roma the 8th f February 2018 by Eric Raymond
It is early days, but the engineered expression of chimeric antigen receptors (CARs) on the surface of T cells the redirection of T‑cell specificitymay lead to improvements in clinical outcomes for patients with solid tumors.
This presentation focuses on the science of Gene Therapy, the techniques of germ-line and somatic gene therapy and the mechanism of curing diseases and disorders using gene therapy. The presentation starts by discussing some common basic terms from genetics and moves on to the historical development of gene therapy techniques in chronological order. The different types of gene therapy techniques and their mechanisms have been discussed in detail subsequently. In concluding slides, some commercially available gene therapy products are mentioned and challenges of gene-therapy techniques have been highlighted.
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptxPRAMESHPANWAR1
Name of the title: Nucleic Acid-Based Therapeutic Delivery System.
It includes information about nucleic acid, gene therapy, and its type, a method to deliver the desired DNA, i.e., vectors and their types, with proper examples and diagrams, and how these things help in delivering a nucleic acid-based therapeutic drug delivery system.
Lectins are carbohydrate-binding proteins or glyco-proteins binding selectively without the involvement of enzymes, Gene responsible for expression lection found in chromosome 10q11.2-q21
Found in plnats grains, legume, soy bean, kidney bean
Lectins recognize tumor marker which play important role for diagnosing tumor cell, screening tumour and able to detect subtle neoplastic changes
In this slide, You will get to learn abut Gene Therapy and different types of gene therapy. Various method of Gene Therapy and Advantage & Disadvantage and Recent advances in Gene Therapy.
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
Ethnobotany and Ethnopharmacology:
Ethnobotany in herbal drug evaluation,
Impact of Ethnobotany in traditional medicine,
New development in herbals,
Bio-prospecting tools for drug discovery,
Role of Ethnopharmacology in drug evaluation,
Reverse Pharmacology.
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxEduSkills OECD
Andreas Schleicher presents at the OECD webinar ‘Digital devices in schools: detrimental distraction or secret to success?’ on 27 May 2024. The presentation was based on findings from PISA 2022 results and the webinar helped launch the PISA in Focus ‘Managing screen time: How to protect and equip students against distraction’ https://www.oecd-ilibrary.org/education/managing-screen-time_7c225af4-en and the OECD Education Policy Perspective ‘Students, digital devices and success’ can be found here - https://oe.cd/il/5yV
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
3. Gene Therapy
“A type of experimental treatment in which
foreign genetic material ( DNA or RNA) is
inserted into a person’s cell to prevent or fight
with cancer”
4. Types of Gene Therapy
• Germ line Germ Therapy
Germ-line gene therapy is when DNA is
transferred into the cells that produce
reproductive cells, eggs or sperm, in the body.
This type of therapy allows for the correction of
disease-causing gene variants that are certain to
be passed down from generation to generation.
5. Types of Gene Therapy
• Somatic Gene Therapy
The theraupautic genes are transferred into
somatic cells of a patient
Any modifications is restricted with in the
individuals
6. Three different types of Approach
1. Immunotherapy
2. Onco-lytic viro therapy
3. Gene transfer
7. Immunotherapy in Cancer
Immunotherapy uses genetically modified cells
and viral particles to stimulate the immune
system to destroy cancer cells.
a. With altered cancer cell
b. With gene invivo
c. Using altered immune cells
11. • Recent clinical trials of second and third generation
vaccines have shown encouraging results with a wide
range of cancers, including lung cancer, pancreatic
cancer, prostate cancer and malignant melanoma.
• As with any cancer monotherapy, combination
therapy using vaccines may be more effective than
vaccine therapy alone.
• Cancer vaccines that have presented only modest
immune response may find usefulness as an adjuvant
therapy for use after surgery or chemotherapy to
eliminate any remaining cancer cells.
12. Genes in-charge - Immunotherapy
Prostate Cancer - Murine (1,3) – galactosyl transferase
Pancreatic Cancer – CEA & MUC-1
Prostate Cancer – GMCSF
Lymphoma Cancer – GMCSF & CD4OL
Melanoma – IL-2
Kidney Cancer – CD-80
13. 2. Oncolytic Agents
“Oncolytic viro therapy, which uses viral
particles that replicate within the cancer cell to
cause cell death”.
• A number of different viruses have been used
for this purpose, including vaccinia,
adenovirus, herpes simplex virus type I,
retrovirus and Newcastle disease virus.
14. Retrovirus
• A retrovirus is a type of RNA virus that inserts a copy of its
genome into the DNA of the host cell that invades, thus
changing the genome of the cell.
• Once inside the host cell’s cytoplasm, the virus uses its own
reverse transcriptase enzyme to produce DNA from its RNA
genome ( the reverse of the usual pattern, thus retro)
• he new DNA is then incorporated into the host
cell genome by an integrase enzyme, at which point the
retroviral DNA is referred to as a provirus. The host cell then
treats the viral DNA as part of its own genome, transcribing
and translating the viral genes along with the cell's own
genes, producing the proteins required to assemble new
copies of the virus.
15. • Oncolytic vectors are designed to infect cancer cells and
induce cell death through the propagation of the virus,
expression of cytotoxic proteins and cell lysis.
• It’s an emerging treatment modality that shows great
promise, particularly with metastatic cancers.
16. 3. Gene transfer
“Gene transfer is a new treatment modality that
introduces new genes into a cancerous cell or the
surrounding tissue to cause cell death or slow the
growth of the cancer”.
• Genes with a number of different functions have
been proposed for this type of therapy, including
Suicide genes (genes that cause cellular death
when expressed)
Anti-angiogenesis genes and
Cellular stasis genes
17. • This treatment technique is very flexible, and
a wide range of genes and vectors are being
used in clinical trials with successful
outcomes.
19. Sterio-type Gene
• p53 – Genome guardian
It act to kill cancer cell, supress cancer cell growth
and prevent cells from becoming cancerous.
Gendicine – drug composed mainly of human p53
tumor supressor gene and modifies adenovirus.
Functions:
Triggering the activity of natural killer cells
Decrease the tumor resistance to radiotherapy
and chemotherapy.
20. Advantages of Gene therapy with
Cancer
It has the potential to kill cancer cells
It gives a chance of life to someone who is
born with mutated cancer gene.
It can be used to eradicate disease from the
future disease.
21. Dis-advantages of Gene therapy with
Cancer
It is a expensive treatment
Gene therapt requires ongoing treatment to
be effective
The genetic testing, screening, research in
finding the availability of certain gene is very
controversy.